Primary Endpoint Met in Study of Postmenopausal Women With Osteoporosis Transitioning From Bisphosphonate Treatment
Immunotherapy Atezolizumab Shrank Tumors in People with a Specific Type of Lung Cancer
UCB clinical trials policy
UCB is committed to providing the opportunity to patients to make informed decisions about participating in clinical trials.
Disclosure Policy of the Astellas Group for Information on Conduct and Results of Clinical Trials.
The Astellas Group (*1) (hereinafter collectively “Astellas”) recognises that making clinical trial information and results more widely available to researchers, healthcare professionals, patients, and interested members of the public will benefit public health. Therefore, Astellas is committed to publicly sharing data on clinical trials that are being performed under its responsibility. To meet this commitment, Astellas will comply with relevant laws, regulatory requirements and industry guidance for registration of clinical trial information and disclosure of clinical trial results.
AstraZeneca establishes Scientific Review Board to support clinical trial data transparency commitment
AstraZeneca today announced the creation of a Scientific Review Board that will act independently to assess requests from external researchers which include patient level data. The Board of independent clinicians and academics has been established as part of AstraZeneca’s commitment to the European Federation of Pharmaceutical Industries and Associations (EFPIA) and Pharmaceutical Research and Manufacturers of America (PhRMA) Responsible Data Sharing Principles, as well as the new European Medicines Agency Clinical Trial Policy and Regulation.
clinical trials are critical for determining the safety and efficacy of new medicines and are integral to Roche’s strategy of developing innovative medicines and diagnostics that address the medical needs of patients.
Roche is committed to sharing data from clinical trials and has registered and posted summary reports for trials involving patients on clinicaltrials.gov and on roche-trials.com since 2005. Alongside this posting, we actively seek presentation and publication of our clinical trial data at scientific congresses and in peer-reviewed journals.
Bausch + Lomb and Nicox Announce FDA Acceptance of New Drug Application for Novel Glaucoma Candidate VESNEO
Valeant Pharmaceuticals International, Inc.’s wholly owned subsidiary, Bausch + Lomb, and Nicox S.A. announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for VESNEO™ (latanoprostene bunod ophthalmic solution 0.024%), an intraocular pressure (IOP) lowering single-agent eye drop dosed once daily, for patients with open angle glaucoma or ocular hypertension. If approved, VESNEO will be the first nitric oxide donating prostaglandin receptor agonist available for the above indication.
